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ABSTRACT
The long-term overall survival of Ewing sarcoma (EWS) patients remains poor; less 
than 30% of patients with metastatic or recurrent disease survive despite aggressive 
combinations of chemotherapy, radiation and surgery. To identify new therapeutic 
options, we employed a multi-pronged approach using in silico predictions of drug 
activity via an integrated bioinformatics approach in parallel with an in vitro screen 
of FDA-approved drugs. Twenty-seven drugs and forty-six drugs were identified, 
respectively, to have anti-proliferative effects for EWS, including several classes of 
drugs in both screening approaches. Among these drugs, 30 were extensively validated 
as mono-therapeutic agents and 9 in 14 various combinations in vitro. Two drugs, 
auranofin, a thioredoxin reductase inhibitor, and ganetespib, an HSP90 inhibitor, were 
predicted to have anti-cancer activities in silico and were confirmed active across 
a panel of genetically diverse EWS cells. When given in combination, the survival 
rate in vivo was superior compared to auranofin or ganetespib alone. Importantly, 
extensive formulations, dose tolerance, and pharmacokinetics studies demonstrated 
that auranofin requires alternative delivery routes to achieve therapeutically effective 
levels of the gold compound. These combined screening approaches provide a rapid 
means to identify new treatment options for patients with a rare and often-fatal 
disease.
INTRODUCTION
Ewing sarcoma (EWS) is a rare, aggressive 
malignancy of neuroectodermal origin that develops 
in bones and, less often, in soft tissues [1]. EWS is the 
second most common bone malignancy after osteosarcoma 
[2], and it frequently develops in pediatric and young 
adult age groups [3]. The incidence of EWS is about 
3/1,000,000 cases per year, with a clear predominance 
in Caucasians. The American Cancer Society estimates 
that 225 children and adolescents are diagnosed with 
EWS in North America each year. The most significant 
prognostic factor for patients with EWS is the presence or 
absence of overt metastatic disease. Metastatic disease is 
most commonly located in the lungs (30%), bone and/or 
bone marrow (30%), and lung metastasis combined with 
bone and/or bone marrow metastasis (20%) [4]. Other 
clinical prognostic factors have been found, such as tumor 
                  Research Paper
Oncotarget4080www.impactjournals.com/oncotarget
location, tumor size, patient age, and pattern of metastasis 
[5]. About 25% of patients show distant metastasis at the 
time of diagnosis [6]. More than 90% of the EWS tumors 
harbor an (11;22) (q24;q12) translocation that encodes 
for a EWS/FLI1 fusion protein [7], which functions as a 
potent oncoprotein with an abnormal transcription factor 
behavior that leads to aberrant expression of numerous 
genes and contributes to tumorigenicity [8, 9].
The current therapies for patients with metastatic 
EWS are limiting. The introduction of the multimodal 
approach in the management of EWS resulted in a 
significant increase in survival for EWS patients. Adding 
chemotherapy to the combination of surgery and radiation 
is essential in treating EWS due to the presence of 
residual tumor after resection and micro-metastasis even 
in localized disease [10]. The front-line chemotherapy 
for EWS is alternating vincristine/doxorubicin/
cyclophosphamide (VDC) and ifosfamide/etoposide (IE) 
[11]. Patients with localized tumors currently have a 75% 
survival rate compared to 10% before the introduction 
of chemotherapy. Unfortunately, patients with metastatic 
disease (about 25% of patients at the time of diagnosis) 
still do poorly with a 20% 5-year-survival rate [7, 10, 12]. 
A high percentage of patients develop metastasis and 
resistance to the current treatment regimens [10], which 
warrants further exploration of possible therapeutic 
targets.
RESULTS
In silico prediction
The systems approach to repurposing drugs has 
recently gained momentum in pursuit of new treatments 
for various diseases [13, 14]. The basic concept is to use 
integrated bioinformatics to identify drugs that can reverse 
the gene expression of a given disease. We extended the 
concept and proposed three computational approaches to 
predict drugs for EWS from a drug library consisting of 
1,335 drugs (Figure 1). First, the top 20 negatively scored 
drug hits that are predicted to reverse the EWS disease 
gene expression were selected (including 13 distinct 
drugs). Second, the top 20 positively scored drug hits 
(including 18 distinct drugs) that share a gene expression 
profile similar to the pattern obtained by the silencing 
of EWS/FLI1 via RNAi approaches (siEWS/FLI1) were 
identified. Third, the top 20 drug hits (including 14 
distinct drugs) that are predicted to reverse the derived 
drug resistance expression signature were selected. 
Some drug hits were repeated within each approach 
or shared among multiple approaches. For example, 
the HSP90 inhibitors, geldanamycin and tanespimycin 
(17-(allylamino)-17-demethoxygeldanamycin, 17-AAG), 
appeared 2 and 4 times, respectively, in the list of the 
resistance-based approach. MS-275, an HDAC inhibitor, 
appeared in both disease-based and siRNA-based 
approach. In total, 43 distinct drugs were predicted using 
the three computational approaches. Twenty-seven of these 
drugs were then manually selected for extensive in vitro 
validation (Figure 1).
In vitro screening
We screened, in parallel to the three computational 
approaches, an FDA-approved drug library containing 
2,316 drugs (1,536 unique chemical entities). A panel of 
sarcoma cell lines including 3 EWS lines, each with a 
confirmed EWS gene rearrangements [15] and two non-
tumorigenic and one benign osteoid osteoma control cell 
lines (Hs 822.T., Hs 863.T., and Hs 919.T.), respectively 
were used (Tables 1 and 2). Hs 882.T. and Hs 863.T. were 
previously reported to be of Ewing sarcoma origin [16]; 
however, FISH analysis and molecular characterization by 
our group failed to identify an EWS gene rearrangement 
(unpublished data). The drug screening study protocol 
employed is summarized in Supplementary Table S1. In 
total, 78 drugs showed activity in at least one or more 
EWS cell lines; however, 29 of the compounds were 
cytotoxic to the non-tumorigenic control cells while 
3 drugs (vincristine, doxorubicin and etoposide) are 
currently prescribed for the treatment of EWS and were 
eliminated from further consideration. Overall, forty-five 
(45) drugs were identified in the primary screen, including 
auranofin (Ridaura®) (Table 2) and were nominated for 
further validation.
Post screen analysis and secondary screen
Next, the predicted and library screened drugs were 
extensively validated. The in vitro activities of each drug 
hit were evaluated in an expanded panel of EWS cell lines 
(either the EWS/FLI1 or the EWS/ERG fusion) (Table 1) 
and confirmed employing 12-point dose-response curves 
ranging from 50 µmol/L to 1 nmol/L, with triplicate 
sampling (Table 3). As mentioned above, one of the most 
notable drug hits discovered through both the in silico and 
in vitro drug screening approaches was auranofin. Based 
on this finding, we subsequently screened auranofin against 
six other marketed or investigational anticancer drug hits 
(carfilzomib, elesclomol, bortezomib, geldanamycin, 
AUY922, and ganetespib, Supplementary Figures S1–S5 
and Figure 2). These drugs were chosen based on their 
known mechanisms and safety profiles. We also tested 
the synergy between these drug hits (Supplementary 
Figures S6–S11). Several classes of agents were found to be 
highly synergistic in combination with auranofin, including 
the next generation HSP90 inhibitors ganetespib (STA-
9090; Synta Pharmaceuticals) and AUY922 (Novartis). 
These independent results peaked our interest since 
geldanamycin and its derivative 17-AAG were repeatedly 
identified in our integrated bioinformatics studies. 
Since the development of geldanamycin and 17-AAG 
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was discontinued due to clinical safety issues observed in 
clinical trials [17], we sought to investigate a lead HSP90 
inhibitor, ganetespib (Synta Pharmaceuticals), which has a 
better risk-benefit profile in clinical trials. We evaluated the 
anti-proliferation effect in combination treatments using 
the EWS and control cell lines. As shown in Figure 2, 
the combined treatment of auranofin and ganetespib 
inhibited cell growth and was highly synergistic across 
all of the EWS lines as opposed to the non-tumorigenic 
cell lines (red shows strong in vitro activity while green 
lack thereof). The above-mentioned screening results were 
deemed sufficient to warrant in vivo preclinical proof of 
principle studies.
The expression of EWS-FLI1 influences 
sensitivity to auranofin
Because auranofin is predicted to mimic the silencing 
of EWS-FLI1 oncogene in the in silico analysis and it 
shows preferential toxicity against Ewing cells harboring 
the EWS-FLI1 chimeric gene as compared with the non-
tumorigenic cells without the EWS-FLI1 gene (Figure 1), 
we then investigated whether Ewing cells are sensitive to 
auranofin if EWS-FLI1 is silenced. To knock down the 
expression of EWS-FLI1 in A673 Ewing cells, we designed 
two different siRNAs, corresponding to the sequence within 
the 3ʹ downstream half of EWS-FLI1 mRNA (siFLI1-#3) 
Figure 1: In silico prediction of drugs for EWS using three approaches. (A) Identify drugs that are likely to reverse disease 
gene expression (disease-based approach). A disease gene expression signature was created from the results of two meta-analysis studies 
[75, 76], where disease tissue samples and normal tissue samples were compared. (B) Identify drugs that mediate gene expression 
similar to siRNA EWS/FLI1 (siEWS/FLI1) (siRNA-based approach). The siEWS/FLI signature was taken from the previous study [77]. 
(C) Identify drugs that are likely to sensitize drug resistance expression (resistance-based approach). A drug resistance expression signature 
was computed by comparing the pre-treatment samples of patients who responded to chemotherapy versus those who did not respond to 
chemotherapy [78]. Drug gene expression databases were built from the CMap 2.0 and part of the LINCS. In the plot, each dot represents 
the score of one drug instance. One drug may have multiple instances due to multiple experiments. False discovery rate (FDR) value < 0.05 
was used to select drug hits and only the top 20 drug hits for each approach were selected. In the heat map, the first column represents 
the disease gene expression ranked by fold change and the remaining columns represent the gene expression of drug hits. Red shows up-
regulated genes and green shows down-regulated genes. All the drug hits from the three approaches were merged and manually evaluated. 
The drugs colored by black were selected for further experimental validation.
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Table 1: EWS fusion status for EWS and non-tumorigenic cell lines
Cell Line EWS Fusion Status
A673 EWS/FLI1 Type I
TC-71 EWS/FLI1 Type I
SK-ES-1 EWS/FLI1 Type II
RD-ES EWS/FLI1 Type II
CHLA-258 EWS/FLI1 Type III
COG-E-352 EWS/ERG fusion
Hs 822.T No fusion detected
Hs 863.T No fusion detected
Hs 919.T No fusion detected
and the sequence of the breakpoint of EWS-FLI1 type I 
mRNA (siBPEF1) respectively. To examine whether the 
siRNAs could abolish the expression of EWS-FLI1, the 
effects of siRNAs on the protein levels of EWS-FLI1 were 
analyzed by western blot (see Supplementary methods). 
Treatment with siFLI1-#3, or to a greater extent, siBPEF1, 
significantly decreased the EWS-FLI1 protein expression 
in A673 cells with type I fusion at 48h after transfection, 
as compared with the siControl treatment (Figure 3A). In 
addition, A673 cells became resistant to auranofin after 
the silencing of EWS-FLI1 gene, as evidenced by the 
significant increase in the IC50 values of A673 cells treated 
by siFLI1-#3 or siBPEF1 followed by the incubation of 
auranofin for 72 h (siFLI1-#3 and siBPEF1 IC50 values 
are above 1.0 µmol/L), as compared with the counterpart of 
the siControl group (siControl, IC50 = 0.27 ± 0.02 µmol/L) 
(Figure 3B). These experiments further validate the in 
silico prediction and suggest a need to further assess its 
potential clinical utility as an anti-cancer agent.
Defining maximum tolerated dose
Ridaura® (auranofin) is typically delivered 
orally (capsules containing 3 mg auranofin) and has 
been repurposed in several clinical trials with limited 
results (i.e., clinicaltrials.gov identifier: NCT01419691, 
NCT02126527, and NCT02126527). We hypothesized 
that the oral bioavailability of auranofin (gold) might 
explain the difference in its anti-cancer activities in vitro 
versus in clinical trials given that the published product 
monograph for Ridaura® capsules stated that the human 
oral bioavailability of gold from Ridaura® capsules is 
only approximately 25% [18, See Supplementary Material 
Reference 18]. Additionally, the ability to increase the dose 
of auranofin to achieve higher blood concentrations of gold 
was limited by dose-limiting gastrointestinal side effects 
(diarrhea, loose stools, nausea, vomiting and abdominal 
cramps) [18, 19]. For our studies we dosed BALB/c 
mice orally at 10 mg/Kg with different formulations of 
auranofin suspensions prepared in 0.5% hydroxypropyl 
methyl cellulose to help assure dose uniformity. We 
compared the ground contents of Ridaura® capsules, 
the ground pure auranofin drug substance, auranofin 
suspension containing 0.5% sodium lauryl sulfate (a 
surfactant), auranofin suspensions with the pH adjusted to 
pH = 1, 4 and 7, auranofin suspension dosed into fasted 
versus high fat diet mice and finally a solution of auranofin 
prepared in 5% dimethyl sulfoxide (DMSO) with a pH = 1. 
Pharmacokinetic studies were conducted on all of these 
formulation variations. Blood samples from 3 mice at each 
time point (0, 1, 2, 4, 8, 12, 24, 48 and 96 hours) and the 
whole blood was assayed by ICPMS for gold.
We additionally studied dose accumulation of the 
gold by comparing a formulation of Ridaura® capsule 
contents as described above and dosing at 10 mg/Kg single 
dose versus dosing the mice once daily for 5 days. The PK 
study compared the gold content in whole blood samples as 
described above for the single dose versus the gold content 
in whole blood samples from the multidose arm with whole 
blood collected at the end of each 24 hour dosing period 
before the next dose (24, 48, 72, 96 and 120 hours) and 
then whole blood collected every 24 hours for 5 additional 
days (144, 168, 192, 216 and 240 hours) and assayed for 
gold content. The results of these formulation and PK 
studies are shown in Supplementary Table S2.
The formulation studies demonstrated that we were 
unable to alter the amount of auranofin (gold) absorbed 
through formulation variations. These findings led us to 
develop and assess injectable (i.v. and i.p.) formulations 
of auranofin. By defining maximum tolerated dose 
(MTD) following i.v. and i.p. administration of solution 
and suspension formulations of auranofin, our intent 
was to evaluate auranofin alone and in combination with 
ganetespib at MTD in mouse xenograft studies using the 
more convenient i.p. route of administration. Following 
administration of the solution formulation of auranofin 
i.v. and i.p., the maximum tolerated dose was estimated 
at 1 mg/kg and 6 mg/kg, respectively. Following a single 
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Table 2: In vitro drug screen hits
Classes Drug
% Inhibition
Hs 919.T. RD-ES SK-ES-1 A673
Camptothecins Topotecan HCl < 50 97 96 97
Camptothecins Irinotecan Hydrochloride < 50 99 98 83
Alkylating agents Melphalan < 50 95 91 < 50
Taxanes Paclitaxel/Taxol < 50 97 96 96
Gold compound Auranofin < 50 100 99 98
Estrogen Estradiol < 50 < 50 < 50 65
17-alpha-alkylated anabolic steroid Methyltestosterone < 50 73 < 50 < 50
Acetanilides; Steroids and Steroid 
Derivatives Vorinostat < 50 61 < 50 < 50
Nitrofurans Nitrofural/Nitrofurazone < 50 52 72 52
Diphenhydramines Clemastine < 50 < 50 < 50 60
organo-selenium Ebselen < 50 95 96 93
Pterins; Keto-Acids Methotrexate/Amethopterin (R,S) < 50 82 < 50 89
Amino Acids L-Glutamic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl] < 50 77 57 85
Carbohydrates Cytosine β-D-arabinofuranoside/Cytarabine < 50 93 98 84
Macrocyclic lactone Rapamycin < 50 62 51 67
Salicylates and Derivatives; Benzene and 
Derivatives; Benzyl Esters; Benzylacetates; 
Methoxyphenols
Mycophenolic Acid < 50 52 < 50 < 50
Benzylisoquinolines
Cycloheximide < 50 74 81 77
(+)-Tubocurarine chloride < 50 51 < 50 < 50
Atractyloside potassium salt < 50 98 99 99
Thienopyridines Ticlopidine < 50 < 50 < 50 66
Inhibitor of electron transfer at complex III Antimycin A < 50 69 < 50 < 50
Pyrvinium pamoate < 50 98 96 84
Pyridine derivatives/analogs
Isoniazid < 50 < 50 < 50 56
Trifluridine < 50 71 < 50 < 50
Floxuridine < 50 92 56 68
Purines and purine derivatives
Azathioprine < 50 < 50 52 < 50
Mercaptopurine < 50 < 50 57 < 50
Thioguanosine < 50 < 50 64 73
Clofarabine < 50 99 98 93
Cladribine < 50 99 89 87
Azaguanine-8 < 50 < 50 < 50 83
Cyclocytidine < 50 83 98 86
Benzimidazoles
Albendazole < 50 93 93 89
Fenbendazole < 50 86 78 75
Mebendazole < 50 95 96 94
Flubendazole < 50 86 86 77
Oxibendazole < 50 80 84 64
Enzyme inhibitor
Oseltamivir < 50 95 98 95
Disulfiram < 50 96 95 99
Raltitrexed < 50 80 51 59
Novobiocin sodium < 50 51 < 50 60
Amorolfine < 50 < 50 < 50 56
Camptothecine (S,+) < 50 97 96 99
AM 404 < 50 < 50 < 50 65
Etoposide < 50 84 84 < 50
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i.p. suspension dose of auranofin, the maximum tolerated 
dose was 16 mg/kg. This dose was reduced to 12 mg/kg 
and dose tolerance was evaluated after 5 daily doses of 
auranofin suspension i.p. to determine the effects of 
the accumulation of gold in the blood due to the slow 
elimination of gold. Based on the i.p. suspension dose 
tolerance studies, the auranofin suspension formulation 
and dose level of 12 mg/kg was selected for evaluation in 
xenograft mouse studies.
Auranofin pharmacokinetics
The single-dose pharmacokinetics of auranofin 
following pre-treatment with i.v. ganetespib were 
characterized to describe systemic gold exposure near 
the dose evaluated in EWS mouse xenograft studies. By 
describing blood gold concentrations in vivo, we are able to 
place the auranofin in vitro IC50 values described in Table 3, 
as well as in vivo tumor response data in proper context.
As indicated previously, auranofin is a complex of 
gold triethylphosphine and thioglucose tetraacetate. Gold 
comprises 29% of auranofin by weight. Auranofin is 
chemically and metabolically highly unstable in solution. 
In our studies, auranofin immediately and completely 
dissociates in plasma and whole blood ex vivo, as well 
as simulated gastric fluid in vitro (unpublished results). 
Following oral administration of 195Au auranofin to humans, 
25% of administered 195Au appears in plasma [19]. Further, 
approximately 40% of absorbed gold distributes into 
erythrocytes with 60% found in plasma [19]. As a result, 
Table 3: In vitro validation of drug hits
Drugs
IC50 (µmol/L)
A673 RD-ES SK-ES-1 TC-71 CHLA-258 COG-E-352 Hs 822.T. Hs 863.T. Hs 919.T.
Vindesine1 < 0.003 < 0.003 < 0.003 NR, < 0.003 NR, < 0.003 < 0.003 0.25 ± 0.01 0.28 ± 0.01 4.58 ± 0.45
Elesclomol2 0.006 ± 0.006 0.05 ± 0.06 0.01 ± 0.001 < 0.003 NR, < 0.003 0.007 ± 0.002 > 20 > 20 > 20
Niclosamide1 7.02 ± 1.23 8.54 ± 1.55 12.5 ± 2.36 0.79 ± 0.47 0.70 ± 0.14 0.42 ± 0.07 15.24 ± 3.51 10.45 ± 2.66 10.56 ± 2.84
Sanguinarine2 0.75 ± 0.14 1.50 ± 0.12 1.87 ± 0.51 0.20 ± 0.08 0.95 ± 0.31 1.05 ± 0.18 1.55 ± 0.26 1.25 ± 0.14 1.44 ± 0.32
Doxazosin2 5.60 ± 1.52 > 25 20.44 ± 5.87 22.5 ± 9.35 16.14 ± 6.78 17.12 ± 6.58 15.65 ± 2.12 14.58 ±3.02 18.48 ± 3.27
Fluphenzaine1 10.52 ± 2.89 14.26 ± 3.21 16.27 ± 3.66 17.00 ± 6.68 18.98 ± 6.79 16.14 ± 7.51 22.65 ± 7.23 20.54 ± 2.88 15.47 ± 3.68
Menadione1 6.80 ± 1.35 10.55 ± 3.20 5.56 ± 1.24 2.94 ± 3.48 3.64 ± 2.08 5.62 ± 1.31 12.20 ± 2.12 14.25 ± 3.20 15.82 ± 2.35
Puromycin1 0.25 ± 0.01 0.35 ± 0.03 0.35 ± 0.10 0.08 ± 0.05 0.06 ± 0.02 0.05 ± 0.01 0.55 ± 0.13 1.02 ± 0.26 0.89 ± 0.03
Alfuzosin2 > 50 > 50 > 50 > 50 > 50 > 50 > 50 > 50 > 50
Daunorubicin2 0.05 ± 0.02 0.05 ± 0.03 0.04 ± 0.03 0.0046 ± 0.0004 < 0.003 < 0.003 0.15 ± 0.12 0.18 ± 0.08 0.42 ± 0.15
MS2751,2 2.5 ± 1.02 2.0 ± 0.85 2.4 ± 1.01 1.53 ± 0.49 0.15 ± 0.03 1.47 ± 0.54 >25 > 25 > 50
Simvastatin2 0.58 ± 0.05 3.25 ± 0.14 3.86 ± 0.89 4.33 ± 3.86 0.25 ± 0.13 10.47 ± 1.70 2.08 ± 0.84 4.10 ± 0.56 2.88 ± 0.58
Auranofin2 0.33 ± 0.22 2.45 ± 0.52 0.08 ± 0.32 0.26 ± 0.14 0.38 ± 0.19 0.82 ± 0.19 1.45 ± 0.09 3.25 ± 0.12 5.38 ± 0.89
Fenbufen2 > 50 > 50 > 50 > 50 > 50 > 50 > 50 > 50 > 50
Lysergol2 > 50 > 50 > 50 > 50 > 50 > 50 > 50 > 50 > 50
Thioridazine1 10.05 ± 1.25 15.02 ± 1.45 15.86 ± 2.47 15.90 ± 1.38 16.06 ± 5.52 10.6 ± 4.37 8.50 ± 1.58 9.24 ± 2.01 8.84 ± 1.29
Trifluoperazine1 15.60 ± 3.55 18.21 ± 2.54 16.68 ± 3.14 16.38 ± 3.46 13.63 ± 4.80 12.10 ± 1.58 10.55 ± 2.45 9.84 ± 2.28 16.82 ± 4.20
(R)-Apomorphine2 8.52 ± 2.14 7.85 ± 1.69 10.55 ± 3.20 17.30 ± 2.21 14.67 ± 6.86 4.01 ± 1.55 14.32 ± 1.47 15.22 ± 2.19 16.68 ± 3.02
Meclofenoxate2 > 50 > 50 > 50 > 50 > 50 > 50 > 50 > 50 > 50
Chlorpromazine1 10.57 ± 2.15 > 25 > 25 17.61 ± 8.63 15.27 ± 4.55 16.14 ± 2.29 16.80 ± 3.22 18.40 ± 3.07 15.49 ± 2.09
Tretinoin2 > 50 > 50 > 50 > 50 4.95 ± 3.82 35.54 ± 6.28 > 50 > 50 > 50
Kinetin2 > 50 > 50 > 50 > 50 > 50 > 50 > 50 > 50 > 50
Evoxine2 
(prestwick−665)
> 50 > 50 > 50 > 50 > 50 > 50 > 50 > 50 > 50
Primaquine2 32.52 ± 6.58 > 25 > 25 14.28 ± 3.71 7.14 ± 2.21 13.33 ± 4.09 > 25 > 25 > 50
Progesterone2,3 > 50 > 50 > 50 > 50 11.5 ± 5.31 24.88 ± 5.85 > 50 > 50 > 50
Anisomycin1 0.12 ± 0.01 0.15 ± 0.02 0.20 ± 0.01 0.04 ± 0.01 0.08 ± 0.01 0.02 ± 0.01 0.15 ± 0.05 0.20 ± 0.01 0.15 ± 0.02
Bortezomib4 0.01 ± 0.003 0.01 ± 0.001 0.02 ± 0.002 0.005 ± 0.0081 0.007 ± 0.03 0.005 ± 0.04 0.45 ± 0.08 0.18 ± 0.03 0.17 ± 0.003
Geldanamycin3 1.93 ± 0.05 0.05 ± 0.003 0.03 ± 0.002 < 0.003 < 0.003 < 0.003 > 20 > 20 > 20
Genatespib4 0.04 ± 0.01 0.02 ± 0.02 0.01 ± 0.001 < 0.003 < 0.003 < 0.003 > 20 > 20 > 20
AUY9224 0.02 ± 0.002 0.009 ± 0.001 0.03 ± 0.002 < 0.003 < 0.003 < 0.003 > 20 > 20 > 20
The hits are annotated based on their source:
1Disease-based approach;
2siRNA-based approach;
3Resistance-based approach; or
4In vitro-based screen and others.
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and consistent with the extensive literature describing 
auranofin pharmacokinetics in animals and humans, 
we characterized the pharmacokinetics of i.p. auranofin 
in mice by quantifying blood gold concentrations as 
summarized in Table 4. Peak blood gold concentrations 
were 12.43 μg/mL in mice receiving auranofin suspension 
preceded by i.v. ganetespib. The apparent elimination 
half-life of gold was 23.7 hours in mice pretreated with 
ganetespib. The area under the blood gold concentration-
time profile, another measure of systemic exposure to gold, 
was 535 hr*μg/mL in mice pretreated with ganetespib. 
Following five consecutive once daily i.p. doses of 12 mg/kg 
auranofin suspension in mice pretreated with ganetespib, 
the trough (plateau) plasma gold concentration (24 hours 
following the fifth daily dose) was 23.9 μg/mL.
The mean single dose Cmax value of 12.43 μg/mL, 
expressed in molar concentration, equals to 63.10 μmol/L 
(Table 4). The mean in vitro IC50 values for auranofin are 
described in Table 3, for each of the EWS cell lines tested, 
ranged from 0.08 to 5.38 μmol/L. IC50 values for gold in 
these cell lines would be 29% of the values presented in 
Table 3. We conclude that systemic drug exposure to gold 
following 12 mg/kg ip auranofin suspension exceeded the 
in vitro IC50 values for auranofin, and for gold, in each 
of the EWS cell lines studied. In addition, blood gold 
concentrations achieved in the studies described in this 
work exceed systemic drug exposure observed in adult 
and pediatric rheumatoid arthritis patients receiving 
therapeutic, chronic doses of auranofin [19, 20].
Auranofin, ganetespib, and the combination 
treatments improved survival of mice in a 
xenograft mouse model
To assess the antitumor activity of auranofin 
(using an alternative delivery approach), ganetespib 
and the combination treatments in vivo, we generated a 
xenograft nude mouse model by injecting A673 cells 
intramuscularly proximal to the tibia. Based on the dose 
tolerance and pharmacokinetic studies described above, 
we administered auranofin at a tolerable daily i.p. dose 
that achieved adequate systemic drug exposure. Auranofin 
was administered with a dose of 12 mg/kg through an i.p. 
injection once a day for 5 days per week, and ganetespib 
was administered with a dose of 150 mg/kg through an 
i.v. injection once weekly. Mice that grew palpable tumors 
were randomized into four groups: vehicle, auranofin-only, 
ganetespib-only, and the combination. The weights of the 
mice were stable among all four arms throughout the 
study, and no major side effects were observed except for 
a skin lesion at the site of the i.v. injection at the base of 
the tail of 2 mice in the ganetespib-only group. The H&E 
Figure 2: Combination analysis for auranofin and ganetespib in six EWS cell lines and three control (Hs 822.T., 
Hs 863.T., and Hs 919.T.) cell lines. Inhibitory concentration values for individual auranofin or ganetespib as well as drug combinations 
are shown. (A) Color scale for drug inhibition values. (B–J) Synergy between auranofin and ganetespib was tested by CellTiter-Glo assay 
at 64 different drug combinations for each cell line. (K) Color scale for Combination Index (CI) values. (L–Q) CI values for auranofin and 
ganetespib combination treatment for six EWS cell lines. CI value of > 1 indicates antagonism effects; CI = 1 indicates additive effects; 
CI value of < 0.9 indicates synergy effects; and CI value of < 0.5 indicates strong synergy effects. (Negative inhibition values cannot be 
used to calculate CI values).
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staining of kidney, liver and spleen tissues showed no sign 
of toxicity. The survival rates were significantly different 
between the auranofin only, ganetespib only, and the 
combination versus control groups (p < 0.05, confidence 
interval 90%). The survival rate in the combination group 
was nearly doubled in this extremely aggressive EWS 
tumor animal model when compared to the control group 
(Figure 3C).
DISCUSSION
Historically, drug development for pediatric cancers 
has only occurred after agents have shown efficacy 
in adult tumors. Clofarabine (approved for refractory 
pediatric acute lymphoblastic leukemia) remains the 
only anti-neoplastic agent ever approved for pediatric 
use prior to adult labeling. Moreover, of the 120 new 
cancer therapeutic agents approved for adults by the year 
2003, only 30 have had a pediatric indication. Of these 
30 drugs, only 15 acquired subsequent pediatric labeling. 
These practices have led to limits in the new agents 
“pipeline” for children and have hindered advancements 
in the treatment of EWS. In 2003, Hirschfeld et al. stated 
that the best opportunity for survival for patients with 
EWS was to identify more effective therapies to apply to 
newly diagnosed patients [21]. Sadly, more than ten years 
later, this remains true and underscores the need for the 
development of novel agents.
The Orphan Drug Act defines a rare disease as one 
that affects less than 200,000 individuals in the United 
States [22, 23]. Approximately 30 million people in the 
United States are living with rare diseases, equating to one 
in every ten Americans. Based on a recent study published 
by DiMasi et al. for the Study of Drug Development, 
costs to develop a new pharmaceutical agent is estimated 
to $2870 million (2013 dollars) [24] The Orphan Drug 
Act provides pharmaceutical companies with incentives 
to develop and commercialize new treatments for 
rare diseases. Despite these incentives; however, the 
development time and costs make it difficult for firms 
to invest in new therapies for diseases such as EWS. 
Drug repurposing, exploring new uses for existing (FDA 
Figure 3: The sensitivity of EWS cells to auranofin is dependent on expression of the EWS-FLI1 oncogene. 
(A) Representative western blot data shows the significant decrease in the expression of EWS-FLI1 in A673 cells 48h post-transfection. 
(B) Cell viability was assessed by the CellTiter Blue assay in A673 cells treated by siControl, siFLI1-#3 or siBPEF1 for 48 h then followed 
by the incubation of auranofin ranging from 7.8 nmol/L to 1 µmol/L for 72h. Data are presented as the mean ± SD of three independent 
experiments performed in triplicate. (C) In vivo studies of auranofin, ganetespib and the combination treatment in an EWS xenograft mice 
model (n = 12 per group). The percentage of survival rate in control, auranofin treated, ganetespib treated, and auranofin in combination 
with ganetespib treated groups.
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approved) and abandoned drugs, represents an opportunity 
to advance new treatments to rare disease patients more 
quickly, and at a lower cost [25–27]. Over the past 
few years, biotech, academia, government and disease 
philanthropy organizations generated successful stories 
using innovative technologies for drug repurposing [28]. 
The National Center for Advancing Translational Sciences 
(NCATS) at the NIH also contributed tremendously to the 
growth in this translational science area. The Learning 
Collaborative, a partnership between the University 
of Kansas Cancer Center (KUCC), the Leukemia and 
Lymphomia Society (LLS) and the NIH’s Therapeutics 
for Rare and Neglected Diseases (TRND) program, has 
played a leadership role nationally in this effort [27]. 
We have leveraged our drug repurposing expertise and 
experiences, along with an innovative in silico integrated 
bioinformatics platform technology (e.g., [13, 29, 30]), to 
not only identify drug repurposing opportunities in EWS, 
but to advance these agents administered alone and in 
combination with other anticancer agents through in vitro 
and in vivo preclinical proof of principle studies.
A systematic approach using in silico prediction 
combined with a traditional drug screening approach 
identified numerous drug repurposing opportunities. 
Molecular profiling data, critical to predicting drug 
activity in silico, is growing rapidly with increasing 
public access. Researchers are now able to combine 
genome-wide proteomics, gene expression profiles, and 
RNA interference data to build computational molecular 
pathology systems. These molecular pathology models can 
then be used to determine drug-disease connections using 
general molecular characteristics [29]. This systematical 
approach to repositioning drugs has now been applied 
to many diseases. Examples include topiramate for 
inflammatory bowel disease [30], trifluoperazine for lung 
cancer [31], and rapamycin for lymphoid malignancies 
[32]. By leveraging public datasets, we predicted 27 out of 
1,335 drugs for in vitro validation. Fifteen out of 27 drugs 
exhibit IC50 values of less than 10 µmol/L in one or more 
EWS cell lines and 10 drugs exhibit IC50 values less 
than 10 µmol/L in all six EWS cell lines tested. Notably, 
6 drugs (auranofin, geldanamycin, vindesine, elesclomol, 
daunorubicin, and MS-275) have IC50 values ten-fold 
less in EWS cell lines than in the three non-tumorigenic 
control cell lines. In addition to the high success rate of 
discovering new drug hits, in silico prediction is relatively 
inexpensive and quick, suggesting its great potential to 
screen compounds.
In addition to the drugs that are predicted to reverse 
the disease gene expression, we identified the drugs 
that share an expression profile similar to the silence of 
EWS/FLI1, a key causative factor in the pathogenesis 
of EWS, and the drugs that may overcome clinical drug 
resistance. Interestingly, the top 20 drug hits among the 
three approaches have little overlap, although some drugs 
may be significant in multiple approaches. For example, 
geldanamycin, a drug predicted by the resistance-based 
approach, is also significant in both disease-based 
approach and siRNA-based approach, but it was ranked 
out of 20. All three approaches led to positive hits, which 
exhibit IC50 values less than 10 µmol/L in EWS cell lines 
in vitro. These results suggested that in silico prediction 
based on different sources is beneficial. Especially, the 
recent efforts on molecular characterization of EWS 
and cellular response to drug treatment provide new 
opportunities to leverage diverse datasets for finding 
therapeutics for EWS [33–35].
Our in vitro drug screen identified 46 hits of drugs. 
These drugs were of diverse classes from alkylating 
agents, steroids, estrogens, and enzyme inhibitors, to 
gold compounds. We prioritized the top 29 hits from in 
silico and in vitro screening that were of potential clinical 
interest and then moved them forward for extensive in 
vitro validation (Table 3).
Among the six most potent drugs from our screens 
(i.e., auranofin, geldanamycin, vindesine, elesclomol, 
daunorubicin, and MS-275), MS-275 and elesclomol are 
the other two drugs that we are pursuing. MS-275 (also 
known as entinostat) is a selective histone deacetylase 
(HDAC) inhibitor which targets HDAC1 and HDAC3, 
and it has been demonstrated to be reasonably safe and 
effective in the treatment of a wide range of cancers, 
including leukemia, lymphoma, melanoma, non-small-cell 
lung cancer and breast cancer, both alone or in combination 
of other therapies [36–42]. Entinostat is currently 
marketed by Syndax and is in the phase III clinical trial 
in combination with exemestane for the treatment of 
patients with hormone receptor-positive advanced breast 
cancer (NCT02115282). Meanwhile, two active phase II 
clinical trials where non-small-cell-lung cancer patients 
will be treated with entinostat before chemotherapy 
(NCT01935947) and anti-PD1 treatment (NCT01928576) 
are ongoing, which indicates the feasibility of combination 
studies of entinostat with other targeted agents as an 
epigenetic-based therapy in EWS treatment. Elesclomol 
(STA-4783) is an investigational drug being developed 
by Synta Pharmaceuticals and GlaxoSmithKline, which 
exerts potent anticancer activity through the elevation 
of reactive oxygen species (ROS) levels and is currently 
in the phase II clinical evaluation as a novel anticancer 
therapeutic in combination with paclitaxel in the treatment 
of recurrent or persistent ovarian cancer (NCT00888615). 
In addition, the Genomics of Drug Sensitivity in Cancer 
(GDSC) database shows that cancer cells with EWS-FLI1 
mutations are preferentially sensitive to elesclomol as 
compare with the wide-type counterparts (http://www.
cancerrxgene.org/translation/Drug/1031#t_scatter_1031), 
which is consistent with our in vitro drug screens. Further 
mechanistic studies of entinostat and elesclomol in 
Ewing sarcoma are underway (Ma and Godwin, personal 
communications). In addition, the analogs of vindesine 
and daunorubicin, named vincristine and doxorubicin, 
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respectively, are the first-line chemotherapies for EWS 
treatment, which further validates our in silico and in vitro 
screening approaches.
In these studies we were drawn to Auranofin 
(Ridaura®) since it was a hit in both in silico and in 
vitro screening. Auranofin is an oral gold complex, first 
approved by FDA for the treatment of rheumatoid arthritis 
in 1985 [43]. However, the mechanism of action of 
auranofin is not completely understood. In addition to its 
anti-inflammatory activity, others and we have reported 
that auranofin is a potent thioredoxin reductase (TrxR) 
inhibitor with both in vitro and in vivo anticancer activities 
[1, 25, 26, 44–54]. TrxR catalyzes the NADPH-dependent 
reduction of oxidized thioredoxin and plays a central role 
in regulating cellular redox homeostasis, cell growth, and 
apoptosis. Increasing evidence shows that TrxR is over-
expressed or constitutively active in many tumor cells. 
Moreover, TrxR appears to contribute to increased tumor 
cell growth and a resistance to chemotherapy. Others have 
proposed that auranofin might be a selective inhibitor of 
the oncogenic protein kinase C iota (PKCι) protein [55], 
but others have yet to confirm. 
As previously reported, Ridaura® was first 
developed for the management of rheumatoid arthritis 
as a disease-modifying anti-rheumatic drug (DMARD) 
[56]. However, the adverse effects and the concerns about 
the long-term consequences of the immunosuppression 
induced by Ridaura® led to the decline in its use [57]. 
Although, auranofin has shown superior activity in 
in vitro screens across several tumor types [49, 58–61], we 
noted that it was not effective in other animal xenograft 
models by our group when given orally (Ma, Pessetto, 
and Godwin, unpublished data). The only in vivo efficacy 
studies using auranofin that showed activity evaluate the 
drug as a suspension/solution delivered i.p. [58, 62], but 
neither studies performed formulations, dose tolerance, 
or pharmacokinetics studies. Therefore, we sought to 
determine if altering the route of delivery could replicate 
the dramatic in vitro anticancer activity and improve its 
efficacy in vivo. Previous studies have shown that orally 
delivered auranofin is rapidly metabolized and intact 
auranofin has never been detected in the blood [63]. 
Thus, studies of the pharmacokinetics of auranofin have 
involved measurement of gold concentrations. Upon oral 
administration, 25% of auranofin gets absorbed [18, 64]. 
The mean terminal plasma half-life of auranofin gold 
at steady state in previous studies was 26 days (range 
21 to 31 days; n = 5). The mean terminal body half-life 
was 80 days (range 42 to 128; n = 5). About 60% of the 
absorbed gold (15% of the administered dose) from a 
single dose of auranofin is excreted in urine; the remaining 
gold is excreted in feces [18]. To more closely mimic the 
in vitro activity of auranofin, we evaluated alternative 
routes of delivery and demonstrated that the amount of 
gold from the i.p. suspension dose is 4 to 5 times that 
obtained by the oral route.
Auranofin has been evaluated in the several cancer 
clinical trials (clinicaltrials.gov). A clinical proof of 
concept trial, evaluating auranofin as a single agent for 
the treatment of chronic lymphocytic leukemia (CLL) was 
recently completed (clinicaltrials.gov, NCT01419691) by 
University of Kansas Medical Center. Based on the initial 
Table 4: Blood gold pharmacokinetic parameters in BALB/c mice following a single i.p. dose of 
12 mg/kg auranofin suspension following pre-treatment with ganetespiba
Treatment Auranofin+Ganetespib
Mean Body Weight (kg) 0.02026
Auranofin Dose (mg/kg)b 12
Gold Dose (mg/kg)c 3.48
Cmax (μg/mL) 12.43
Cmax (μmol/L) 6.31
Tmax (hr) 8.0
AUC0∫
∞ (μg*hr/mL) 536.26
Kel (hr
-1) 0.029
T½ (hr) 23.7
Cl/F (mL/hr/kg) 6.49
Trough (μg/mL)d 23.87
aN = 30, N = 3 per serial blood collection time point, ten serial blood samples collected over 48 hours.
bAuranofin injectable suspension formulation contained 0.67 mg/ml of auranofin and 0.5% HPMC K4M in D5W. Mice 
were pretreated with 150 mg/kg ganetespib i.v. approximately 24 hours prior to the administration of the single i.p. dose of 
auranofin.
cOn a weight basis, auranofin contains 29% gold. Therefore, the i.p. dose of gold administered was 3.48 mg/kg.
dTrough sample was collected 24 hours following the fifth once daily i.p. dose.
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results in CLL, a multi-center clinical proof of concept 
trial is currently being initiated to evaluate auranofin in 
combination with bortezomib for the treatment of Mantle 
Cell Lymphoma (Weir, personal communications). In a 
recent clinical study, Jatoi and colleagues reported that 
10 asymptomatic ovarian cancer patients with elevated 
CA-125 received 3 mg of auranofin orally twice per day 
and were evaluated for up to ~6 months. Although well 
tolerated, oral delivery of auranofin had little effect or no 
effect on improving progress-free survival; the median 
PFS was 2.8 months (95% CI: 1.3–3.8) [65], further 
suggesting our idea that the gold levels obtained via oral 
delivery may be insufficient to achieve its optimal anti-
cancer effects.
The other class of drugs identified in our study 
is HSP90 inhibitors. HSP90 is a highly conserved 
molecular chaperone protein that aids in the stability 
and proper folding of client proteins. It is vital for cell 
transformation, proliferation, and survival. Client proteins 
that are dependent on HSP90 were identified in cancer 
hallmarks such as growth and evasion of apoptosis. 
Thus, HSP90 is considered as a potential target for 
cancer therapy [66, 67]. Our validation screen identified 
three HSP90 inhibitors: geldanamycin, ganetespib, and 
AUY922. Geldanamycin, a benzoquinone ansamycin 
with antibiotic and antitumor activities, was one of earliest 
HSP90 inhibitors [68, 69]. The dependence on NAD(P)
H:quinone oxidoreductase and the gastrointestinal and 
hepatic toxicities limited geldanamycin and its derivatives’ 
clinical use. Ganetespib and AUY922 emerged as second-
generation, non-geldanamycin HSP90 inhibitors with 
better pharmacokinetics and safety profiles [70, 71]. 
Ganetespib inhibits HSP90 protein by acting on the 
ATP-binding domain at the N-terminus and has shown 
a preclinical antitumor activity in several solid and 
hematological tumors [17, 67, 68, 72, 73]. AUY922 is 
an isoxazole-based HSP90 inhibitor that antagonizes the 
ATPase activity of the protein. It has shown in vitro and 
in vivo potent antitumor activity [72, 73]. Thirty eight 
studies found for ganetespib on CllinicalTrials.gov. Two 
trials were terminated with results as of July 20, 2016 
(NCT01798485 and NCT01227018).
Even though the NCT01798485 trial showed no 
safety issues with ganetespib, Synta suspended the phase 3 
study of ganetespib in combination with docetaxel versus 
docetaxel alone in patients with advanced non-small-cell 
lung cancer. NCT01227018, a phase 2 study STA-9090 
as second or third-line therapy for metastatic pancreas 
cancer, was terminated due to interim analysis found the 
study drug to be ineffective (15 patients were enrolled). 
Three trials are recruiting patients with small cell lung 
cancer, epithelial ovarian cancer, fallopian tube cancer, 
primary peritoneal cancer, and breast cancer.
In the in vivo study, auranofin via i.p. delivery, 
ganetespib, and the combination treatments significantly 
increased the survival rate of the mice. The new route 
of delivery of auranofin alone or in combination with 
ganetespib did not show any noticeable toxicity or 
adverse effects, except for a tail lesion in two mice 
at the site of the i.v. injection of ganetespib. In all, 
auranofin, an FDA-approved drug for the oral treatment 
of rheumatoid arthritis, and ganetespib, an investigational 
HSP90 inhibitor, were predicted to have activity in EWS. 
Activity was subsequently confirmed in vitro via primary 
and secondary screens. In vivo proof of principle was 
demonstrated in a validated xenograft mouse model 
of EWS. When given in combination, auranofin and 
ganetespib were synergistic; however, reformulation of 
auranofin was required to achieve anti-cancer levels of the 
gold particle, suggesting caution when repurposing certain 
drugs for cancer therapies, i.e., the potential need to 
“repurpose” the formulation and delivery of a repurposed 
drug for cancer therapy. Efforts are underway to translate 
these findings to a clinical proof of concept study in EWS 
patients with this debilitating and often-fatal disease.
MATERIALS AND METHODS
Compound library 
The FDA-approved drug library was provided by 
the Lead Development and Optimization Shared Resource 
(LDOSR) within the NCI Cancer Center at the University 
of Kansas. The library contains 2,316 FDA-approved 
drugs (1,536 unique chemical entities) with known 
bioavailability and safety profile in humans. Drugs were 
present at a concentration of 10 mmol/L in DMSO. For 
validation, auranofin was synthesized at the University 
of Kansas and provided by LDOSR with a purity of 
100%. Ganetespib was gifted by Synta Pharmaceuticals 
(Dr. David Proia). Other drugs were purchased from 
SelleckChem.
Cell culture
The A673 cell line, an EWS cell line [74], was kindly 
provided by Dr. Mizuki Azuma (University of Kansas, 
Lawrence, KS). A673 cells were cultured in Dulbecco’s 
modified Eagle’s medium supplemented with 2 mM 
L-glutamine and 10% fetal bovine serum (FBS). TC-71, 
COG-E-352 and CHLA-258 cell lines were obtained 
from Children’s Oncology Group Cell Culture and the 
Xenograft Repository (Texas Tech University Health 
Sciences Center, TX). TC-71, COG-E-352, and CHLA-
258 cell lines were maintained in Iscove’s Modified 
Dulbecco’s Medium supplemented with 20% FBS, 
2 mM L-glutamine and 1XITS (American Type Culture 
Collection, ATCC, Manassas, VA). RD-ES (cultured in 
RPMI-1640 medium with 15% FBS), SK-ES-1 (cultured 
in McCoy’s 5A medium with 10% FBS) cell lines were 
purchased from ATCC. Hs 822.T and Hs 863.T (both 
purported to be derived from EWS), and Hs 919.T 
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(derived from an osteoid tumor) were also purchased from 
ATCC and were cultured in Dulbecco’s Modified Eagle’s 
Medium with 10% FBS. All cell lines were supplemented 
with 1% penicillin/streptomycin and were maintained in 
a 5% CO2 atmosphere at 37°C. The EWS fusion status of 
each cell line is shown below (Table 1).
In silico prediction
Three in silico approaches (disease-based, siRNA-
based, resistance-based approach) were used to predict 
drugs for EWS. The workflow is shown in Figure 1 and the 
details of the methods are described in the supplementary 
material. Briefly, first, the drugs that are predicted to reverse 
disease gene expression were identified. The disease gene 
expression signature was created as the overlap of the 
signatures from two meta-analysis studies [75, 76]. Next, 
since the EWSR1/FLI1 fusion gene is thought to be a 
causative mutation in most EWS, we searched for drugs 
that possess the gene expression profile similar to the 
silence of EWS/FLI1. The siRNA of EWS/FLI1 (siEWS/
FLI1) mediated signature was obtained from the previous 
study [77]. Lastly, since a large number of EWS patients 
are resistant to chemotherapy, we searched for drugs that 
were predicted to sensitize drug resistance. The drug 
resistance signature was computed by comparing the pre-
treatment samples of patients responding to chemotherapy 
and those responding poorly to chemotherapy [78]. 
Drug expression signature database was built from the 
Connectivity Map (CMap) [79] and part of the Library of 
Integrated Cellular Signatures (LINCS, http://lincscloud.
org). The drug signatures that are not robust across multiple 
experiments were removed. The comparison of disease 
signatures and drug signatures was described previously 
[13]. The negative score shows the drug signature is anti-
correlated with the disease signature and the positive score 
shows the drug signature is correlated with the disease 
signature. A false discovery rate (FDR) value of less than 
0.05 was used to select hits and only the top 20 hits in 
each approach were selected for in vitro validation. The 
drug hits predicted from the three approaches were merged. 
We further manually selected drugs for in vitro validation 
based on their availability in the in vitro screening library, 
novelty and potential side effects. 
In vitro high-throughput screening
Drugs or vehicle (DMSO) were preloaded by the 
LDOSR as 250 nL aliquots on an Echo550 platform to 
each well to give a final concentration of 1 µmol/L in a 
total of 25 µL. Cells were grown to 80–90% confluence, 
harvested and aliquoted into 384-well plates (black µClear 
microplates, Greiner bio-one, Germany) at concentrations 
of 750–1,500 cells per well in a total volume of 25 µl/well 
using a Matrix Wellmate (Thermo Scientific). Cells were 
cultured for 72 hours in a 5% CO2 atmosphere at 37°C. 
Aliquots of 25 µl CellTiter-Glo® Reagent (Promega) were 
added directly to each well, the plates were incubated at 
room temperature for 20 min and the luminescence signal 
was measured according to the manufacturer’s protocol. 
The measurements were made using Infinite® M200 Pro 
plate reader (Tecan, Switzerland). Performance of the 
assay was calculated and the Z’ factors were ≥ 0.5 [80]. 
Data were normalized to percentage inhibition. Samples 
exhibiting > 50% growth inhibition in the presence of 
1 µmol/L drug were classified as positive hits.
Hits validation and combination study
For hits validation and combination study, cells 
were harvested and aliquoted into 384-well plates at 
concentrations of 750–1,500 cells per well in a total of 
20 µl/well using a Matrix Wellmate (Thermo Scientific). 
Five µl of culture media containing either vehicles 
or drug were added to each well the next day (drug 
concentrations range from 1 nmol/L to 50 µmol/L). 
For combination study, selected drugs were archived 
in robotically accessible plates, to which media was 
added in preparation for addition to master plates by a 
Nimbus 96 liquid-dispensing workstation (Hamilton). 
Liquid transfers to dilution and assay plates were handled 
using the same workstation. Each 384-well master plate 
contained four 9 by 9 dose-matrix blocks, with eight serial 
two-fold dilutions (concentrations range from 7.8 nmol/L 
to 1 µmol/L). Additional wells were reserved for 
untreated, and vehicle-treated control wells. Cell 
proliferation was evaluated using Cell-Titer Glo® reagents 
(Promega). IC50 values were determined for each drug 
using SigmaPlot (Systat Software). The combination 
index values were calculated using SigmaPlot (Systat 
Software) and CompuSyn [25, 81–83].
Auranofin and ganetespib formulations
A parenteral suspension formulation was prepared 
to support IP administration of auranofin in EWS 
mouse xenograft studies. The injectable suspension 
formulation contained 0.67 mg/ml of auranofin with 
0.5% Hydroxypropyl methylcellulose (HPMC, viscosity 
grade K4M) in 5% dextrose in water for injection (D5W). 
Ganetespib was administered using an injectable solution 
formulation (20% Cremophor RH40 and 80% D5W) 
provided by Synta Pharmaceuticals.
Auranofin dose tolerance studies
The auranofin dose tolerance and pharmacokinetics 
study protocols were approved by the KU-Lawrence 
Institutional Animal Care and Use Committee (KU-
IACUC). Subchronic dose tolerance studies were 
conducted in BALB/c mice to support the design of EWS 
mouse xenograft studies. By establishing the Maximum 
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Tolerated Dose (MTD), we defined the upper limit of 
doses selected for EWS mouse xenograft and in vivo 
pharmacokinetics studies. Mice received a single dose 
of auranofin solution and suspension administered by 
i.v. and i.p. routes of administration. Following a starting 
dose of 1 mg/kg, doses were escalated in subsequent 
mice until intolerable drug-related adverse effects were 
observed. MTD was defined as the maximum dose that 
was not associated dose-limiting adverse effects in mice. 
The MTD was confirmed in a group of 3 mice. Mice were 
continuously monitored for up to 4 hours post-dose.
Auranofin pharmacokinetics
The single-dose plasma pharmacokinetics of 
gold were characterized in 36 BALB/c mice following 
administration of a single 12 mg/kg i.p. suspension 
dose of auranofin. The mice were pretreated 24 hours 
prior to auranofin, with a single 150 mg/kg i.v. dose 
of ganetespib. Blood samples for determination of 
blood gold concentration were obtained prior to, and at 
5, 15, 30 and 60 minutes, 2, 4, 8, 12, 24 and 48 hours 
following administration of auranofin. In addition, a 
trough (plateau) blood sample, collected at 24 hours post-
dose, was obtained in mice following the fifth of five 
consecutive 12 mg/kg once daily i.p. doses of auranofin 
suspension. Blood samples were collected from each 
animal via cardiac puncture. Whole blood aliquots of 
500 µL obtained from each of the three animals per 
time point were assayed using a validated inductively 
coupled plasma mass spectrometry (ICPMS) method 
to quantify blood gold concentration. Mean blood gold 
concentrations were determined for each blood collection 
time point. Non-parametric pharmacokinetic data 
analysis was performed on the resultant mean blood gold 
concentration-time data using WinNonLin®, Version 6.2 
(Centara USA, Inc, St. Louis, MO).
In vivo xenograft mouse model
The guidelines adopted by the Institutional Animal 
Care and Use Committee of the University of Kansas 
Medical Center (KUMC-IACUC) were followed in all 
performed procedures. All experimental protocols were 
approved by KUMC-IACUC. Homozygous athymic nude 
(Foxn1nu/Foxn1nu) female mice at the age of 4-weeks 
were purchased from Jackson Laboratories. After one 
week, one million A673 cells in PBS (pH = 7.3) were 
injected into mice. The cells were injected intramuscularly 
proximal to the tibia and treatment started after 15 days 
of inoculation. Mice developing palpable tumors were 
divided into 4 arms and treated for up to 18 days: vehicle 
(20% Cremophor RH40 and 80% D5W iv and 0.5% 
HPMC K4M ip), auranofin (12 mg/kg i.p. injection 5 days 
per week), ganetespib (150 mg/kg i.v. injection once 
weekly), as well as auranofin and ganetespib combined. 
Mice were evaluated for overall health and weighed every 
week. When tumor size impeded mobility, mice were 
sacrificed and necropsies were performed. Tumors were 
then dissected, measured and processed for analysis. The 
liver, kidneys, and spleen were also snap frozen in liquid 
nitrogen or fixed in 10% neutral buffered formalin and 
paraffin embedded for toxicity studies. Tissues were then 
subjected to hematoxylin and eosin (H&E) staining and 
immunohistochemical staining. The immunohistochemical 
staining method and antibodies used in the study were 
listed in the supplementary data.
Data analysis and statistics
In vitro data were reported as mean ± SD of 3 
independent experiments. In the statistical analyses 
for the in vivo xenograft study, Kaplan-Meier survival 
curves were used to determine the difference in survival 
among the treatment groups. A p-value less than 0.05 
was considered as statistically significant. All statistical 
analyses were performed using SigmaPlot 12.3 (Systat 
Software, Inc. CA, USE).
ACKNOWLEDGMENTS AND FUNDING
This work was supported in part by grants from 
the NCI (R01 CA106588; to A.K. Godwin), the NIH 
(UL1 TR000001-02S1; to S.J. Weir and A.K. Godwin; 
R01 GM079719 to A.J. Butte), the KU Cancer Center 
Support Grant (P30 CA168524), and a CTSA grant from 
NCATS awarded to Z.Y. Pessetto through the University 
of Kansas Medical Center for Frontiers: The Heartland 
Institute for Clinical and Translational Research 
# KL2TR000119. This work was also supported by a 
MCA Partners Advisory Board grant from Children’s 
Mercy Hospital (CMH) and The University of Kansas 
Cancer Center (KUCC). The contents are solely the 
responsibility of the authors and do not necessarily 
represent the official views of the NIH, NCATS, NCI, 
or NIGMS. We would like to thank the KUCC’s Lead 
Development and Optimization Shared Resource 
(LDOSR) for providing the drug library and technical 
support and a member of the KUCC’s Biospecimen 
Repository Core Facility staff, Tara Meyer, for her 
support in H&E and immunohistochemical staining 
experiments. The authors would also like to acknowledge 
support from the Kansas Bioscience Authority Eminent 
Scholar Program to A.K Godwin, the Ewing Marion 
Kauffman Foundation, University of Kansas Endowment 
Association, the Braden’s Hope Foundation, and 
the Massman Family Foundation. Dr. Godwin is the 
Chancellors Distinguished Chair in Biomedical Sciences 
endowment at KUMC.
CONFLICTS OF INTEREST
All authors claim there is no conflicts of interest.
Oncotarget4092www.impactjournals.com/oncotarget
Authors’ contributions
AKG, ZYP, SJW, AJB, BC, and KAN conceived 
and designed the experiments. ZYP, BC, HA, MB, SJW, 
YM, HGR and AKG wrote the main manuscript text. ZYP 
prepared Figures 2 and S1–S11, Tables 2–3 and S1. ZYP, 
HA, SH and YM prepared Figure 3. BC prepared Figure 1. 
CAF and MB prepared Tables 4 and S2. HA prepared table 
1. All authors reviewed the manuscript.
REFERENCES
 1. Ross KA, Smyth NA, Murawski CD, Kennedy JG. The 
biology of ewing sarcoma. ISRN Oncol. 2013; 2013: 
759725. doi:10.1155/2013/759725.
 2. Ordonez JL, Osuna D, Herrero D, de Alava E, Madoz-
Gurpide J. Advances in Ewing’s sarcoma research: where 
are we now and what lies ahead? Cancer Res. 2009; 
69:7140–50. doi:10.1158/0008-5472.CAN-08-4041.
 3. Rodriguez-Galindo C, Navid F, Liu T, Billups CA, Rao BN, 
Krasin MJ. Prognostic factors for local and distant control 
in Ewing sarcoma family of tumors. Ann Oncol. 2008; 
19:814–20. doi:10.1093/annonc/mdm521.
 4. Pinkerton CR, Bataillard A, Guillo S, Oberlin O, Fervers B, 
Philip T. Treatment strategies for metastatic Ewing’s 
sarcoma. Eur J Cancer. 2001; 37:1338–44. doi:
 5. Rodriguez-Galindo C, Liu T, Krasin MJ, Wu J, Billups CA, 
Daw NC, Spunt SL, Rao BN, Santana VM, Navid F. 
Analysis of prognostic factors in ewing sarcoma family of 
tumors: review of St. Jude Children’s Research Hospital 
studies. Cancer. 2007; 110:375–84. doi:10.1002/cncr.22821.
 6. Esiashvili N, Goodman M, Marcus RB, Jr. Changes in 
incidence and survival of Ewing sarcoma patients over 
the past 3 decades: Surveillance Epidemiology and End 
Results data. J Pediatr Hematol Oncol. 2008; 30:425–30. 
doi:10.1097/MPH.0b013e31816e22f3.
 7. Chaturvedi A, Hoffman LM, Welm AL, Lessnick SL, 
Beckerle MC. The EWS/FLI Oncogene Drives Changes 
in Cellular Morphology, Adhesion, and Migration 
in Ewing Sarcoma. Genes Cancer. 2012; 3:102–16. 
doi:10.1177/1947601912457024.
 8. Sankar S, Lessnick SL. Promiscuous partnerships in 
Ewing’s sarcoma. Cancer Genet. 2011; 204:351–65. 
doi:10.1016/j.cancergen.2011.07.008.
 9. Jedlicka P. Ewing Sarcoma, an enigmatic malignancy of likely 
progenitor cell origin, driven by transcription factor oncogenic 
fusions. Int J Clin Exp Pathol. 2010; 3:338–47. doi:
10. Ahmed AA, Zia H, Wagner L. Therapy resistance 
mechanisms in Ewing’s sarcoma family tumors. Cancer 
Chemother Pharmacol. 2014; 73:657–63. doi:10.1007/
s00280-014-2392-1.
11. Womer RB, West DC, Krailo MD, Dickman PS, 
Pawel BR, Grier HE, Marcus K, Sailer S, Healey JH, 
Dormans JP, Weiss AR. Randomized controlled trial of 
interval-compressed chemotherapy for the treatment of 
localized Ewing sarcoma: a report from the Children’s 
Oncology Group. J Clin Oncol. 2012; 30:4148–54. 
doi:10.1200/JCO.2011.41.5703.
12. Balamuth NJ, Womer RB. Ewing’s sarcoma. Lancet Oncol. 
2010; 11:184–92. doi:10.1016/S1470-2045(09)70286-4.
13. Sirota M, Dudley JT, Kim J, Chiang AP, Morgan AA, 
Sweet-Cordero A, Sage J, Butte AJ. Discovery and 
preclinical validation of drug indications using compendia 
of public gene expression data. Sci Transl Med. 2011; 3: 
96ra77. doi:10.1126/scitranslmed.3001318.
14. Vicent S, Sayles LC, Vaka D, Khatri P, Gevaert O, Chen R, 
Zheng Y, Gillespie AK, Clarke N, Xu Y, Shrager J, 
Hoang CD, Plevritis S, et al. Cross-species functional 
analysis of cancer-associated fibroblasts identifies a critical 
role for CLCF1 and IL-6 in non-small cell lung cancer 
in vivo. Cancer Res. 2012; 72:5744–56. doi:10.1158/0008-
5472.can-12-1097.
15. Giovannini M, Biegel JA, Serra M, Wang JY, Wei YH, 
Nycum L, Emanuel BS, Evans GA. EWS-erg and EWS-
Fli1 fusion transcripts in Ewing’s sarcoma and primitive 
neuroectodermal tumors with variant translocations. J Clin 
Invest. 1994; 94:489–96. doi:10.1172/JCI117360.
16. Teicher BA, Bagley RG, Rouleau C, Kruger A, Ren Y, 
Kurtzberg L. Characteristics of human Ewing/PNET 
sarcoma models. Ann Saudi Med. 2011; 31:174–82. 
doi:10.4103/0256-4947.78206.
17. Neckers L, Workman P. Hsp90 molecular chaperone 
inhibitors: are we there yet? Clin Cancer Res. 2012; 
18:64–76. doi:10.1158/1078-0432.ccr-11-1000.
18. Inc. PL. RIDAURA® (auranofin) Capsules. 2011. (See 
Supplementary Material Reference 18).
19. Inc. XP. RIDAURA® Auranofin Capsules 3 mg product 
monograph. Retrieved from http://www.xediton.com/
RIDAURA_PRODUCT%20MONOGRAPH.pdf. 2010. doi:
20. Giannini EH, Brewer EJ, Person DA. Blood gold 
concentrations in children with juvenile rheumatoid arthritis 
undergoing long-term oral gold therapy. Ann Rheum Dis. 
1984; 43:228–31. doi:
21. Hirschfeld S, Ho PT, Smith M, Pazdur R. Regulatory 
approvals of pediatric oncology drugs: previous experience 
and new initiatives. J Clin Oncol. 2003; 21:1066–73. 
doi:10.1200/JCO.2003.11.138.
22. Melnikova I. Rare diseases and orphan drugs. Nat Rev Drug 
Discov. 2012; 11:267–8. doi:10.1038/nrd3654.
23. (2013). Orphan Drug Act. In: FDA, ed. 21.
24. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the 
pharmaceutical industry: New estimates of R&D costs.
25. Pessetto ZY, Ma Y, Hirst JJ, von Mehren M, Weir SJ, 
Godwin AK. Drug repurposing identifies a synergistic 
combination therapy with imatinib mesylate for 
gastrointestinal stromal tumor. Mol Cancer Ther. 2014; 
13:2276–87. doi:10.1158/1535-7163.mct-14-0043.
Oncotarget4093www.impactjournals.com/oncotarget
26. Pessetto ZY, Weir SJ, Sethi G, Broward MA, Godwin AK. 
Drug repurposing for gastrointestinal stromal tumor. Mol 
Cancer Ther. 2013; 12:1299–309. doi:10.1158/1535-7163.
MCT-12-0968.
27. Weir SJ, DeGennaro LJ, Austin CP. Repurposing approved 
and abandoned drugs for the treatment and prevention of 
cancer through public-private partnership. Cancer Res. 
2012; 72:1055–8. doi:10.1158/0008-5472.can-11-3439.
28. Lipton SA, Nordstedt C. Partnering with Big Pharma-What 
Academics Need to Know.
29. Dudley JT, Schadt E, Sirota M, Butte AJ, Ashley E. Drug 
discovery in a multidimensional world: systems, patterns, 
and networks. J Cardiovasc Transl Res. 2010; 3:438–47. 
doi:10.1007/s12265-010-9214-6.
30. Dudley JT, Sirota M, Shenoy M, Pai RK, Roedder S, 
Chiang AP, Morgan AA, Sarwal MM, Pasricha PJ, 
Butte AJ. Computational repositioning of the anticonvulsant 
topiramate for inflammatory bowel disease. Sci Transl Med. 
2011; 3: 96ra76. doi:10.1126/scitranslmed.3002648.
31. Yeh CT, Wu AT, Chang PM, Chen KY, Yang CN, Yang SC, 
Ho CC, Chen CC, Kuo YL, Lee PY, Liu YW, Yen CC, 
Hsiao M, et al. Trifluoperazine, an antipsychotic agent, 
inhibits cancer stem cell growth and overcomes drug 
resistance of lung cancer. Am J Respir Crit Care Med. 2012; 
186:1180–8. doi:10.1164/rccm.201207-1180OC.
32. Wei G, Twomey D, Lamb J, Schlis K, Agarwal J, Stam RW, 
Opferman JT, Sallan SE, den Boer ML, Pieters R, 
Golub TR, Armstrong SA. Gene expression-based chemical 
genomics identifies rapamycin as a modulator of MCL1 and 
glucocorticoid resistance. Cancer Cell. 2006; 10:331–42. 
doi:10.1016/j.ccr.2006.09.006.
33. Tirode F, Surdez D, Ma X, Parker M, Le Deley MC, 
Bahrami A, Zhang Z, Lapouble E, Grossetete-Lalami S, 
Rusch M, Reynaud S, Rio-Frio T, Hedlund E, et al. 
Genomic landscape of Ewing sarcoma defines an aggressive 
subtype with co-association of STAG2 and TP53 mutations. 
Cancer Discov. 2014; 4:1342–53. doi:10.1158/2159-8290.
CD-14-0622.
34. Crompton BD, Stewart C, Taylor-Weiner A, Alexe G, 
Kurek KC, Calicchio ML, Kiezun A, Carter SL, Shukla SA, 
Mehta SS, Thorner AR, de Torres C, Lavarino C, et al. 
The genomic landscape of pediatric Ewing sarcoma. 
Cancer Discov. 2014; 4:1326–41. doi:10.1158/2159-8290. 
CD-13-1037.
35. Brohl AS, Solomon DA, Chang W, Wang J, Song Y, 
Sindiri S, Patidar R, Hurd L, Chen L, Shern JF, Liao H, 
Wen X, Gerard J, et al. The genomic landscape of the 
Ewing Sarcoma family of tumors reveals recurrent STAG2 
mutation. PLoS Genet. 2014; 10: e1004475. doi:10.1371/
journal.pgen.1004475.
36. Gojo I, Jiemjit A, Trepel JB, Sparreboom A, Figg WD, 
Rollins S, Tidwell ML, Greer J, Chung EJ, Lee MJ, 
Gore SD, Sausville EA, Zwiebel J, et al. Phase 1 and 
pharmacologic study of MS-275, a histone deacetylase 
inhibitor, in adults with refractory and relapsed acute 
leukemias. Blood. 2007; 109:2781–90. doi:10.1182/
blood-2006-05-021873.
37. Kummar S, Gutierrez M, Gardner ER, Donovan E, 
Hwang K, Chung EJ, Lee MJ, Maynard K, Kalnitskiy M, 
Chen A, Melillo G, Ryan QC, Conley B, et al. Phase 
I trial of MS-275, a histone deacetylase inhibitor, 
administered weekly in refractory solid tumors and 
lymphoid malignancies. Clin Cancer Res. 2007; 13:5411–7. 
doi:10.1158/1078-0432.CCR-07-0791.
38. Gore L, Rothenberg ML, O’Bryant CL, Schultz MK, 
Sandler AB, Coffin D, McCoy C, Schott A, Scholz C, 
Eckhardt SG. A phase I and pharmacokinetic study of the 
oral histone deacetylase inhibitor, MS-275, in patients with 
refractory solid tumors and lymphomas. Clin Cancer Res. 
2008; 14:4517–25. doi:10.1158/1078-0432.CCR-07-1461.
39. Hauschild A, Trefzer U, Garbe C, Kaehler KC, Ugurel S, 
Kiecker F, Eigentler T, Krissel H, Schott A, Schadendorf D. 
Multicenter phase II trial of the histone deacetylase inhibitor 
pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-
carbamate in pretreated metastatic melanoma. Melanoma 
Res. 2008; 18:274–8. doi:10.1097/CMR.0b013e328307c248.
40. Pili R, Salumbides B, Zhao M, Altiok S, Qian D, Zwiebel J, 
Carducci MA, Rudek MA. Phase I study of the histone 
deacetylase inhibitor entinostat in combination with 13-cis 
retinoic acid in patients with solid tumours. Br J Cancer. 
2012; 106:77–84. doi:10.1038/bjc.2011.527.
41. Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, 
Coleman B, Sebree R, Rodgers K, Hooker CM, Franco N, 
Lee B, Tsai S, Delgado IE, et al. Combination epigenetic 
therapy has efficacy in patients with refractory advanced 
non-small cell lung cancer. Cancer Discov. 2011; 1:598–607. 
doi:10.1158/2159-8290.CD-11-0214.
42. Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, 
Munster PN, Klein PM, Cruickshank S, Miller KD, Lee MJ, 
Trepel JB. Randomized phase II, double-blind, placebo-
controlled study of exemestane with or without entinostat in 
postmenopausal women with locally recurrent or metastatic 
estrogen receptor-positive breast cancer progressing on 
treatment with a nonsteroidal aromatase inhibitor. J Clin 
Oncol. 2013; 31:2128–35. doi:10.1200/JCO.2012.43.7251.
43. Chen X, Shi X, Wang X, Liu J. Novel use of old drug: Anti-
rheumatic agent auranofin overcomes imatinib-resistance of 
chronic myeloid leukemia cells. Cancer Cell Microenviron. 
2014; 1. doi:10.14800/ccm.415.
44. Chen X, Shi X, Zhao C, Li X, Lan X, Liu S, Huang H, 
Liu N, Liao S, Zang D, Song W, Liu Q, Carter BZ, et 
al. Anti-rheumatic agent auranofin induced apoptosis 
in chronic myeloid leukemia cells resistant to imatinib 
through both Bcr/Abl-dependent and -independent 
mechanisms. Oncotarget. 2014; 5:9118–32. doi:  10.18632/
oncotarget.2361.
45. Madeira JM, Bajwa E, Stuart MJ, Hashioka S, Klegeris A. 
Gold drug auranofin could reduce neuroinflammation 
by inhibiting microglia cytotoxic secretions and primed 
respiratory burst. J Neuroimmunol. 2014. doi:10.1016/j.
jneuroim.2014.08.615.
Oncotarget4094www.impactjournals.com/oncotarget
46. Cox AG, Brown KK, Arner ES, Hampton MB. The 
thioredoxin reductase inhibitor auranofin triggers apoptosis 
through a Bax/Bak-dependent process that involves 
peroxiredoxin 3 oxidation. Biochem Pharmacol. 2008; 
76:1097–109. doi:10.1016/j.bcp.2008.08.021.
47. Fan C, Zheng W, Fu X, Li X, Wong YS, Chen T. 
Enhancement of auranofin-induced lung cancer cell 
apoptosis by selenocystine, a natural inhibitor of TrxR1 
in vitro and in vivo. Cell Death Dis. 2014; 5: e1191. 
doi:10.1038/cddis.2014.132.
48. Liu C, Liu Z, Li M, Li X, Wong YS, Ngai SM, Zheng W, 
Zhang Y, Chen T. Enhancement of auranofin-induced 
apoptosis in MCF-7 human breast cells by selenocystine, 
a synergistic inhibitor of thioredoxin reductase. PLoS One. 
2013; 8: e53945. doi:10.1371/journal.pone.0053945.
49. Liu JJ, Liu Q, Wei HL, Yi J, Zhao HS, Gao LP. Inhibition 
of thioredoxin reductase by auranofin induces apoptosis 
in adriamycin-resistant human K562 chronic myeloid 
leukemia cells. Pharmazie. 2011; 66:440–4. doi:
50. Marzano C, Gandin V, Folda A, Scutari G, Bindoli A, 
Rigobello MP. Inhibition of thioredoxin reductase by 
auranofin induces apoptosis in cisplatin-resistant human 
ovarian cancer cells. Free Radic Biol Med. 2007; 42:872–
81. doi:10.1016/j.freeradbiomed.2006.12.021.
51. Pratesi A, Gabbiani C, Michelucci E, Ginanneschi M, 
Papini AM, Rubbiani R, Ott I, Messori L. Insights on 
the mechanism of thioredoxin reductase inhibition 
by gold N-heterocyclic carbene compounds using the 
synthetic linear selenocysteine containing C-terminal 
peptide hTrxR(488-499): an ESI-MS investigation. 
J Inorg Biochem. 2014; 136:161–9. doi:10.1016/j.
jinorgbio.2014.01.009.
52. Di Sarra F, B. F, Bini R, Saielli G, Bagno A. Reactivity 
of Auranofin with Selenols and Thiols - Implications for 
the Anticancer Activity of Gold(I) Compounds. Eur J Inorg 
Chem. 2013; 2013:2718–27. doi:10.1002/ejic.201300058.
53. Rigobello MP, Messori L, Marcon G, Agostina Cinellu M, 
Bragadin M, Folda A, Scutari G, Bindoli A. Gold complexes 
inhibit mitochondrial thioredoxin reductase: consequences 
on mitochondrial functions. J Inorg Biochem. 2004; 
98:1634–41. doi:10.1016/j.jinorgbio.2004.04.020.
54. Gromer S, Arscott LD, Williams CH, Jr., Schirmer RH, 
Becker K. Human placenta thioredoxin reductase. Isolation 
of the selenoenzyme, steady state kinetics, and inhibition 
by therapeutic gold compounds. J Biol Chem. 1998; 
273:20096–101. doi:
55. Wang Y, Hill KS, Fields AP. PKCiota maintains a tumor-
initiating cell phenotype that is required for ovarian 
tumorigenesis. Mol Cancer Res. 2013; 11:1624–35. 
doi:10.1158/1541-7786.MCR-13-0371-T.
56. Roder C, Thomson MJ. Auranofin: repurposing an old 
drug for a golden new age. Drugs R D. 2015; 15:13–20. 
doi:10.1007/s40268-015-0083-y.
57. Kean WF, Kean IR. Clinical pharmacology of gold. 
Inflammopharmacology. 2008; 16:112–25. doi:10.1007/
s10787-007-0021-x.
58. Fiskus W, Saba N, Shen M, Ghias M, Liu J, Gupta SD, 
Chauhan L, Rao R, Gunewardena S, Schorno K, 
Austin CP, Maddocks K, Byrd J, et al. Auranofin induces 
lethal oxidative and endoplasmic reticulum stress 
and exerts potent preclinical activity against chronic 
lymphocytic leukemia. Cancer Res. 2014; 74:2520–32. 
doi:10.1158/0008-5472.CAN-13-2033.
59. Park SH, Lee JH, Berek JS, Hu MC. Auranofin displays 
anticancer activity against ovarian cancer cells through 
FOXO3 activation independent of p53. Int J Oncol. 2014; 
45:1691–8. doi:10.3892/ijo.2014.2579.
60. Kim NH, Park HJ, Oh MK, Kim IS. Antiproliferative effect 
of gold(I) compound auranofin through inhibition of STAT3 
and telomerase activity in MDA-MB 231 human breast 
cancer cells. BMB Rep. 2013; 46:59–64. doi:
61. Nakaya A, Sagawa M, Muto A, Uchida H, Ikeda Y, 
Kizaki M. The gold compound auranofin induces 
apoptosis of human multiple myeloma cells through 
both down-regulation of STAT3 and inhibition of 
NF-kappaB activity. Leuk Res. 2011; 35:243–9. 
doi:10.1016/j.leukres.2010.05.011.
62. Liu N, Li X, Huang H, Zhao C, Liao S, Yang C, Liu S, 
Song W, Lu X, Lan X, Chen X, Yi S, Xu L, et al. Clinically 
used antirheumatic agent auranofin is a proteasomal 
deubiquitinase inhibitor and inhibits tumor growth. 
Oncotarget. 2014; 5:5453–71. doi: 10.18632/oncotarget.2113.
63. Tepperman K, Finer R, Donovan S, Elder RC, Doi J, 
Ratliff D, Ng K. Intestinal uptake and metabolism of 
auranofin, a new oral gold-based antiarthritis drug. Science. 
1984; 225:430–2. doi:
64. Kean WF, Hart L, Buchanan WW. Auranofin. Br J 
Rheumatol. 1997; 36:560–72. doi:
65. Jatoi A, Radecki Breitkopf C, Foster NR, Block MS, 
Grudem M, Wahner Hendrickson A, Carlson RE, Barrette B, 
Karlin N, Fields AP. A mixed-methods feasibility trial 
of protein kinase C iota inhibition with auranofin in 
asymptomatic ovarian cancer patients. Oncology. 2015; 
88:208–13. doi:10.1159/000369257.
66. Du X, Li Y, Jing X, Zhao L. Effect of a heat shock protein 
90-specific inhibitor on the proliferation and apoptosis 
induced by VEGF-C in cervical cancer cells. Exp Ther Med. 
2014; 8:1559–64. doi:10.3892/etm.2014.1930.
67. Singh A, Singh A, Sand JM, Bauer SJ, Bin Hafeez B, 
Meske L, Verma AK. Topically Applied Hsp90 Inhibitor 
17AAG Inhibits Ultraviolet Radiation-Induced Cutaneous 
Squamous Cell Carcinomas. J Invest Dermatol. 2014. 
doi:10.1038/jid.2014.460.
68. Jhaveri K, Taldone T, Modi S, Chiosis G. Advances in the 
clinical development of heat shock protein 90 (Hsp90) 
inhibitors in cancers. Biochim Biophys Acta. 2012; 
1823:742–55. doi:10.1016/j.bbamcr.2011.10.008.
69. Yu Y, Szczepek AJ, Haupt H, Mazurek B. Geldanamycin 
induces production of heat shock protein 70 and partially 
attenuates ototoxicity caused by gentamicin in the 
organ of Corti explants. J Biomed Sci. 2009; 16: 79. 
doi:10.1186/1423-0127-16-79.
Oncotarget4095www.impactjournals.com/oncotarget
70. Proia DA, Bates RC. Ganetespib and HSP90: translating 
preclinical hypotheses into clinical promise. Cancer Res. 
2014; 74:1294–300. doi:10.1158/0008-5472.CAN-13-3263.
71. Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, 
Valenti M, Patterson L, de Haven Brandon A, Gowan S, 
Boxall F, Aherne W, Rowlands M, Hayes A, et al. 
NVP-AUY922: a novel heat shock protein 90 inhibitor 
active against xenograft tumor growth, angiogenesis, 
and metastasis. Cancer Res. 2008; 68:2850–60. 
doi:10.1158/0008-5472.CAN-07-5256.
72. Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ, 
Inoue T, Chen L, Li D, Carretero J, Li YC, Sinha P, 
Carey CD, Borgman CL, et al. Ganetespib (STA-9090), a 
nongeldanamycin HSP90 inhibitor, has potent antitumor 
activity in in vitro and in vivo models of non-small 
cell lung cancer. Clin Cancer Res. 2012; 18:4973–85. 
doi:10.1158/1078-0432.CCR-11-2967.
73. Sessa C, Shapiro GI, Bhalla KN, Britten C, Jacks KS, 
Mita M, Papadimitrakopoulou V, Pluard T, Samuel TA, 
Akimov M, Quadt C, Fernandez-Ibarra C, Lu H, et al. 
First-in-human phase I dose-escalation study of the HSP90 
inhibitor AUY922 in patients with advanced solid tumors. 
Clin Cancer Res. 2013; 19:3671–80. doi:10.1158/1078-
0432.CCR-12-3404.
74. Martinez-Ramirez A, Rodriguez-Perales S, Melendez B, 
Martinez-Delgado B, Urioste M, Cigudosa JC, Benitez J. 
Characterization of the A673 cell line (Ewing tumor) by 
molecular cytogenetic techniques. Cancer Genet Cytogenet. 
2003; 141:138–42. doi:
75. Kauer M, Ban J, Kofler R, Walker B, Davis S, Meltzer P, 
Kovar H. A molecular function map of Ewing’s sarcoma. 
PLoS One. 2009; 4: e5415. doi:10.1371/journal.
pone.0005415.
76. Hancock JD, Lessnick SL. A transcriptional profiling meta-
analysis reveals a core EWS-FLI gene expression signature. 
Cell Cycle. 2008; 7:250–6. doi:
77. Prieur A, Tirode F, Cohen P, Delattre O. EWS/FLI-
1 silencing and gene profiling of Ewing cells reveal 
downstream oncogenic pathways and a crucial role for 
repression of insulin-like growth factor binding protein 3. 
Mol Cell Biol. 2004; 24:7275–83. doi:10.1128/
MCB.24.16.7275-7283.2004.
78. Schaefer KL, Eisenacher M, Braun Y, Brachwitz K, Wai DH, 
Dirksen U, Lanvers-Kaminsky C, Juergens H, Herrero D, 
Stegmaier S, Koscielniak E, Eggert A, Nathrath M, et al. 
Microarray analysis of Ewing’s sarcoma family of tumours 
reveals characteristic gene expression signatures associated 
with metastasis and resistance to chemotherapy. Eur J 
Cancer. 2008; 44:699–709. doi:10.1016/j.ejca.2008.01.020.
79. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, 
Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, 
Hieronymus H, Wei G, et al. The Connectivity Map: using 
gene-expression signatures to connect small molecules, 
genes, and disease. Science. 2006; 313: 1929--35. doi:
80. Inglese J, Shamu CE, Guy RK. Reporting data from 
high-throughput screening of small-molecule libraries. 
Nature chemical biology. 2007; 3:438–41. doi:10.1038/
nchembio0807-438.
81. Chou TC. Drug combination studies and their synergy 
quantification using the Chou-Talalay method. Cancer Res. 
2010; 70:440–6. doi:10.1158/0008-5472.can-09-1947.
82. Chou TC. The mass-action law based algorithm for 
cost-effective approach for cancer drug discovery and 
development. Am J Cancer Res. 2011; 1:925–54. doi:
83. Chou TC. Theoretical basis, experimental design, and 
computerized simulation of synergism and antagonism in 
drug combination studies. Pharmacol Rev. 2006; 58:621–
81. doi:10.1124/pr.58.3.10.
